about
Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource SettingsMicrocomputer-aided diagnosis in cardiology. An expert system based on clinical and phono-mechanocardiographic data.Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry.Unusual manifestations of disseminated neoplasia at presentation: right-sided heart failure due to a massive cardiac metastasis and autoimmune thrombocytopenia in pleomorphic rhabdomyosarcoma of the adult.Lobe-specific heterogeneity in asymmetric dimethylarginine and matrix metalloproteinase levels in a rat model of obstructive cholestasisInter-regional comparisons of the prevalence of cardiometabolic risk factors in patients with hypertension in Europe: the GOOD survey.Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosisOral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.An update on hypertensive emergencies and urgencies.Lung ultrasound in internal medicine: A bedside help to increase accuracy in the diagnosis of dyspnea.Role of matrix metalloproteinases in cholestasis and hepatic ischemia/reperfusion injury: A review.New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.The burden of chronic noncommunicable diseases in undocumented migrants: a 1-year survey of drugs dispensation by a non-governmental organization in Italy.Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.Effects of a Bioavailable Arabinoxylan-enriched White Bread Flour on Postprandial Glucose Response in Normoglycemic Subjects.A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis.Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A case-control study.Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.Myeloperoxidase-Related Chlorination Activity Is Positively Associated with Circulating Ceruloplasmin in Chronic Heart Failure Patients: Relationship with Neurohormonal, Inflammatory, and Nutritional Parameters.Dynamic right and left ventricular interactions in the rabbit: simultaneous measurement of ventricular pressure-volume loops.Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.[Role of ACE-inhibitors in preventing atrial fibrillation relapses in normotensive patients].Alterations in early filling dynamics predict the progression of compensated pressure overload hypertrophy to heart failure better than abnormalities in midwall systolic shortening.Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective.[The evaluation of the end-ejection pressure-length relation as an index of regional contractility]Preservation of the baroreceptor heart rate reflex by chemical sympathectomy in experimental heart failure.Gender-related risk of myocardial involvement in systemic amyloidosis.Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis.Adenosine A1 and A2A receptor cross-talk during ageing in the rat myocardium.The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44.The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).The potential advantage of omapatrilat: dual anti-fibrotic and anti-inflammatory effects in one single molecule.As we cannot afford to renounce to new generation echocardiography in systemic amyloidosis.Diflunisal in late-onset FAP patients with moderate to severe neuropathy.Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients.Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide.Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.
P50
Q30391917-71BB73AE-CA16-44E0-AF5B-7C8B72823211Q31064136-29EA7AD1-B0D4-435B-BBDA-0CB457ECCE5AQ31825779-51EF8739-3B31-459E-9B25-4D64388A38EAQ33370210-954DF395-47B2-43BC-86F5-E939A62C8F6DQ33821707-5B1A46A8-9567-4D42-9A40-A6B837FA6A53Q34878952-C55C1673-CA25-41AD-89C7-10AA5BD014A3Q35002777-221AD516-1D08-44F0-B1F0-31CDF4094260Q36862339-45F9F7C9-AC8E-4F47-A443-DB3DCA443259Q37337552-CDE4B16D-D215-4F5A-B538-18B7F15EEF67Q37676296-39CDB8C5-DDE2-4963-A506-48B3A47DA84FQ38313023-00566738-8403-4531-A491-98EA70FAB1AFQ38631801-73D3271D-534E-42F0-8CD1-DA51CB3AF11BQ38635618-BA6A3D36-B6FF-472F-B408-F73A3538A57CQ39024208-3E806C9E-30E1-40A0-AC1F-3B606EDB2D23Q39118574-BAFB8692-E5E1-435F-AFC9-D734C6AA994AQ39192295-E24A5CB8-018C-4233-9B54-43E119A55BFAQ39859621-D25811F1-912E-42E6-8EDB-801E05C17D31Q40355511-15E6B7F7-E69A-4F21-B159-ECB10F9D2FE2Q40716131-B583D44B-AC1E-48D6-8927-76ACFEBAFE19Q41489706-B7C88B3B-A9E7-4D86-BA03-99858753E82CQ41871114-4500A4FB-B9C1-4FBC-97C0-8B38FC83BB59Q42635036-4B45640B-FE34-4313-9AFC-39010AC2A23AQ43121287-076AC8BA-A558-455B-B8E4-D04E2732CAECQ43196702-C4AA69A0-FD54-443B-AF8C-5A0F1365849AQ43424401-C290AC08-3F0E-4EA7-96AF-F35747FB1890Q43598098-0C15F6EB-773C-4C2A-96C5-74F4DCCCE4A6Q44081089-621860DF-43D7-4AA6-8E04-D7896CE95908Q44102072-8D2E44C6-A7E0-4DBB-A48C-F685E2540C6DQ44135752-6EC76A9A-ACD2-43B8-8A8D-861C94FCE73BQ44538488-47B310AF-1935-410D-B04E-C8D57D050237Q44547126-FC633044-6FF9-490B-A823-02A4B236BB4FQ44707562-837196B7-118B-473F-80C5-03F2E8E4B424Q45168852-E0169732-7B9F-42D7-BE2F-080915587873Q45232252-4CF0360B-1081-4258-82BD-8665E50B7A9EQ45832241-F2D68295-41D1-47AB-976E-F7C5F6E74CD1Q45851008-88C375EB-FD80-4CAE-9D88-BF4B2CBE595FQ46177705-F15E6C77-53AE-4B47-B406-9FAF001611EFQ46194651-ED1DD051-221A-41CD-8360-DAD08FDD7234Q46380099-3452E7C7-F367-4600-9F66-9965B5258296Q46909999-EBA118D9-FC60-4E22-827E-2AE32CE608DB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stefano Perlini
@ast
Stefano Perlini
@en
Stefano Perlini
@es
Stefano Perlini
@nl
type
label
Stefano Perlini
@ast
Stefano Perlini
@en
Stefano Perlini
@es
Stefano Perlini
@nl
prefLabel
Stefano Perlini
@ast
Stefano Perlini
@en
Stefano Perlini
@es
Stefano Perlini
@nl
P106
P1153
7003461147
P21
P31
P496
0000-0002-0320-8574